Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Amagasaki-city, Japan Clinical Trials

A listing of Amagasaki-city, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (37) clinical trials

Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer Patients

Study design:This is a multi-center, observational study in Japan. Patients with newly diagnosed FIGO stage III - IV advanced OC will be enrolled sequentially. In this study, data of 200 subjects will be collected at approximately 20 sites in Japan. To reduce regional bias of study sites, the number of …

Phase N/A

0.08 miles

Learn More »

ADYNOVATE Drug Use-Results Survey

The purpose of this survey is to understand the following items in the actual clinical use of ADYNOVATE in patients: Unexpected adverse drug reactions Occurrence of adverse drug reactions in the actual clinical use Factors that may affect safety and efficacy Occurrence of Factor VIII inhibitor development in patients with …

Phase N/A

4.89 miles

Learn More »

Survey Study for Velaglucerase Alfa (VPRIV) in Japan

The objective of this post-marketing survey study is to collect data to determine the safety and efficacy of velaglucerase alfa (VPRIV) in participants with Gaucher disease who are new to therapy or have been switched from another therapeutic agent for Gaucher disease.

Phase N/A

5.23 miles

Learn More »

ISTODAX for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

To ascertain the safety and efficacy of Istodax in actual clinical settings in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who receive Istodax. Planned registration period 3 years and 6 months Planned surveillance period 4 years and 6 months

Phase N/A

5.67 miles

Learn More »

Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ Tablets

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. RA can reduce the ability to perform everyday tasks. The purpose of this study is to observe the incidence of serious infections, regardless of their relationship to RINVOQ, in Japanese daily practice. RINVOQ …

Phase N/A

5.82 miles

Learn More »

Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners

Through observation of patients with X-linked hypophosphatemic rickets/osteomalacia (XLH) for up to 5 years, the study intends to collect data that allow achievement of the following objectives To determine medical characteristics of the disease and the disease process To determine physical and psychological burden on patients as well as economic …

Phase N/A

6.1 miles

Learn More »

FASENRA SCEI for Long-term Use

The purpose of the investigation is to confirm the followings under the post-marketing actual long-term use of FASENRA Subcutaneous Injection 30 mg Syringe. Detection of unexpected Adverse Drug Reactions To grasp development of Adverse Drug Reactions To grasp contributing factors possibly having an impact on the safety and efficacy Development …

Phase N/A

6.1 miles

Learn More »

Lynparza Breast Cancer Clinical Experience Investigation

To characterise the development of adverse drug reactions (ADRs) of bone marrow depression in patients with unresectable or recurrent BRCA mutated HER2 negative breast cancer who have previously received anticancer chemotherapy under actual post-marketing use.

Phase N/A

6.1 miles

Learn More »

Brilinta Clinical Experience Investigation

To confirm the following safety topics in patients to be treated with BRILINTA tablets 60 mg or 90 mg (hereinafter referred to as "BRILINTA") in clinical practice in the post-marketing phase. Profile and incidence of ADRs The CEI will be conducted to collect data of the events, especially focusing on …

Phase N/A

6.1 miles

Learn More »

Dominantly Inherited Alzheimer Network (DIAN)

Dominantly inherited Alzheimer's disease (AD) represents less than 1% of all cases of AD and is an important model for study because the responsible mutations have known biochemical consequences that are believed to underlie the pathological basis of the disorder. Three major hypotheses will be tested: First, that there is …

Phase N/A

6.1 miles

Learn More »